<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4623666/results/search/test_trace/results.xml">
  <result pre="Abstract There has been growing use of highly active antiretroviral" exact="treatment" post="(HAART) for HIV and significant progress in developing prophylactic"/>
  <result pre="focus on single feedback mechanisms: for instance, HAART optimism makes" exact="infection" post="less scary and thus promotes risky sexual behavior. Here,"/>
  <result pre="of unprotected sex, but it also increases perceived risk of" exact="infection" post="and, on longer timescales, causes demographic impacts that partially"/>
  <result pre="under-estimate intervention coverage. Age-specific effects cause sexual behavior and HIV" exact="prevalence" post="to change in opposite ways in old and young"/>
  <result pre="have sex with men (MSM) in the United States7. Fortunately," exact="treatment" post="options such as Highly Active Antiretroviral Treatment (HAART), are"/>
  <result pre="prophylactic HIV vaccine is now a realistic goal8. However, implementing" exact="treatment" post="and prevention programs may have unintended consequences. Interventions like"/>
  <result pre="cause some individuals to become complacent about their risk of" exact="infection" post="and thus increase their risky sexual behavior, thereby also"/>
  <result pre="the factors that may drive its emergence. In terms of" exact="treatment" post="commitment, one such study comprising of a mass questionnaire"/>
  <result pre="the individuals characterized as pessimistic13. The study authors concluded that" exact="treatment" post="centres should more closely monitor patients’ prognostic beliefs. Studies"/>
  <result pre="a deterministic compartmental model that treats HIV risk behavior and" exact="infection" post="as linked processes wherein the individual increases risk behavior"/>
  <result pre="contracting HIV. Ramadanovic et al. demonstrate that HIV incidence and" exact="prevalence" post="only decline above threshold levels of HAART coverage, indicating"/>
  <result pre="constant, they were able to determine thresholds at which HIV" exact="prevalence" post="would increase instead of decrease due to the vaccine,"/>
  <result pre="modifying vaccines provide only a low degree of protection against" exact="infection" post="and/or generate high fitness ratios. Their findings report that"/>
  <result pre="with both uninfected and potentially infected partners, if the perceived" exact="prevalence" post="of infection is sufficiently low22. Applying a decision-making model"/>
  <result pre="uninfected and potentially infected partners, if the perceived prevalence of" exact="infection" post="is sufficiently low22. Applying a decision-making model to infectious"/>
  <result pre="can better understand the changes in behavior associated with new" exact="treatment" post="options. We use the model to shed light on"/>
  <result pre="(5) the impact of HAART and prophylactic vaccines on HIV" exact="infection" post="probabilities and HIV natural history. Vital Dynamics and Partner"/>
  <result pre="individuals in the model are younger, and both the perceived" exact="prevalence" post="of HIV in a population as well as the"/>
  <result pre="can adjust k to reflect an individual’s belief of the" exact="prevalence" post="of the vaccine in the population. This parameter is"/>
  <result pre="the end of the AIDS stage (or the AIDS with" exact="treatment" post="stage, see subsection on HAART below). The different stages"/>
  <result pre="stage, see subsection on HAART below). The different stages of" exact="infection" post="are illustrated by Supplementary Figure S1. During unprotected sex,"/>
  <result pre="a susceptible person with a probability dependent on their current" exact="infection" post="stage, with the relative infectivity during the various stages"/>
  <result pre="when HAART should be initiated, since the benefits of early" exact="treatment" post="can be counteracted by antiviral drug toxicity34. Here, we"/>
  <result pre="an individual enters HAART with probability ρ, where ρ represents" exact="treatment" post="coverage. HAART lengthens life, facilitates relative reduction in transmission,"/>
  <result pre="unprotected HIV− individual. As no HIV vaccine currently exists, our" exact="testing" post="assumption is based on practice associated with the Hepatitis"/>
  <result pre="presence of HAART and vaccines, and (3) may transmit the" exact="infection" post="if they have unprotected sex. The model is outlined"/>
  <result pre="how these changes depend on model parameters governing vaccine and" exact="treatment" post="coverage, vaccine efficacy, duration of protection, risk perception parameters,"/>
  <result pre="is HIV+ (which we hereafter refer to simply as &quot;perceived" exact="infection" post="risk&quot;), and per capita number of unprotected sex acts"/>
  <result pre="to equilibrium levels of population size, HIV prevalence, and perceived" exact="infection" post="risk (b) (Figs 1 and 2). HIV prevalence is"/>
  <result pre="and perceived infection risk (b) (Figs 1 and 2). HIV" exact="prevalence" post="is highest in 20–29 and 30–39 year olds. The"/>
  <result pre="highest in 20–29 and 30–39 year olds. The average perceived" exact="infection" post="risk bt is similar to the HIV prevalence, although"/>
  <result pre="the HIV prevalence, although HIV− individuals tend to underestimate HIV" exact="infection" post="risk and HIV+ individuals tend to slightly overestimate it."/>
  <result pre="and HIV+ individuals tend to slightly overestimate it. The perceived" exact="infection" post="risk tends to be lowest in 15–19 year olds."/>
  <result pre="increases HIV prevalence, as well as the average bt-value (perceived" exact="infection" post="risk) (Supplementary Figure S2). Increasing the utility for protected"/>
  <result pre="the utility for protected sex (UPS) decreases both the HIV" exact="prevalence" post="and the average perceived infection risk (Supplementary Figure S3)."/>
  <result pre="(UPS) decreases both the HIV prevalence and the average perceived" exact="infection" post="risk (Supplementary Figure S3). This occurs because having a"/>
  <result pre="Impact of HAART on risk perception, sexual behavior, and HIV" exact="prevalence" post="Parameters for the baseline HAART scenario appear in Table"/>
  <result pre="age range due to longer lifespans and delayed age at" exact="infection" post="(Fig. 3d). As a result of reduced transmission rates,"/>
  <result pre="HIV− individuals grows considerably, causing a decrease in overall HIV" exact="prevalence" post="(Fig. 3a,f). In the short-term, HAART optimism causes a"/>
  <result pre="also increases the average value of bt representing the perceived" exact="infection" post="risk, across most age groups, and for both HIV+"/>
  <result pre="individuals (Fig. 3b,c,e versus Fig. 1). The increase in perceived" exact="infection" post="risk has a protective effect on the population, by"/>
  <result pre="benefits of HAART in reducing transmission and increasing the perceived" exact="infection" post="risk are strong enough to counteract how HAART optimism"/>
  <result pre="US more attractive, resulting in a net reduction in HIV" exact="prevalence" post="and incidence. HAART optimism operates through the model parameter"/>
  <result pre="d = 20, US becomes increasingly attractive, which increases actual post-treatment HIV" exact="prevalence" post="as well as the average perceived infection risk (Supplementary"/>
  <result pre="actual post-treatment HIV prevalence as well as the average perceived" exact="infection" post="risk (Supplementary Figure S4). For d &amp;gt; 60, the post-treatment HIV"/>
  <result pre="infection risk (Supplementary Figure S4). For d &amp;gt; 60, the post-treatment HIV" exact="prevalence" post="exceeds the pre-treatment HIV prevalence: for these parameter values,"/>
  <result pre="HAART less attractive to HIV− individuals and thus decreasing HIV" exact="prevalence" post="(with an accompanying decrease in perceived infection risk) (Supplementary"/>
  <result pre="thus decreasing HIV prevalence (with an accompanying decrease in perceived" exact="infection" post="risk) (Supplementary Figures S5, and S6). Univariate sensitivity analysis"/>
  <result pre="being an HIV− person exhibiting HAART optimism, meaning their perceived" exact="prevalence" post="of HIV will increase. Hence, they opt for protected"/>
  <result pre="indeed what is observed in simulations: as k increases, HIV" exact="prevalence" post="decrease (Supplementary Figure S7). However, the average bt-value also"/>
  <result pre="the average bt-value also decreases, since a decrease in HIV" exact="prevalence" post="also causes a decrease in US offers. Hence, the"/>
  <result pre="of HAART (ρ) decreases HIV prevalence, while the average perceived" exact="infection" post="risk, bt, increases slightly, at baseline parameter values (Supplementary"/>
  <result pre="transmission rate (τ) increases the HIV prevalence, and the perceived" exact="infection" post="risk among HIV+ individuals, but has no effect on"/>
  <result pre="among HIV+ individuals, but has no effect on the perceived" exact="infection" post="risk among HIV− individuals (Supplementary Figure S9). This occurs"/>
  <result pre="protected sex (UPS) makes it more attractive, and decreases HIV" exact="prevalence" post="as well as perceived infection risk among both HIV+"/>
  <result pre="more attractive, and decreases HIV prevalence as well as perceived" exact="infection" post="risk among both HIV+ and HIV− individuals (Supplementary Figure"/>
  <result pre="US as an HIV+ individual, since they cannot acquire the" exact="infection" post="while protected, which makes US offers attractive to vaccinated"/>
  <result pre="5d). The intervention causes a particularly rapid reduction in HIV" exact="prevalence" post="in the 15–20 year-old age group (Fig. 5d). Because"/>
  <result pre="(Fig. 5c). A delayed and more moderate decrease in HIV" exact="prevalence" post="occurs in infected 30–39 year-olds, but the number of"/>
  <result pre="the number of HIV− individuals increases, which reduces the HIV" exact="prevalence" post="(Fig. 5a,f). Individuals have some awareness of the age"/>
  <result pre="to the parameter k. The vaccine program decreases the perceived" exact="prevalence" post="of HIV among HIV− individuals under 29 years of"/>
  <result pre="29 years of age, causes a slight increase in perceived" exact="prevalence" post="in 30–39 year olds, but it has no effect"/>
  <result pre="US. Results are similar among HIV+ individuals, except the perceived" exact="prevalence" post="decreases slightly in 30+ year olds (Fig. 5c). The"/>
  <result pre="in 30+ year olds (Fig. 5c). The decrease in perceived" exact="prevalence" post="in younger age categories occurs due to awareness of"/>
  <result pre="as evidence of vaccinated status. Hence, the decline in perceived" exact="prevalence" post="tracks the decline in actual prevalence, even though US"/>
  <result pre="the waning of protection from the vaccine. Because (1) perceived" exact="infection" post="risk tracks HIV prevalence (Fig. 5b,c) and (2) the"/>
  <result pre="from the vaccine. Because (1) perceived infection risk tracks HIV" exact="prevalence" post="(Fig. 5b,c) and (2) the per capita rates of"/>
  <result pre="k, such that individuals under-estimate population vaccine coverage, the perceived" exact="infection" post="risk increases since individuals interpret US offers as evidence"/>
  <result pre="US offers as evidence of HIV+ status. This causes HIV" exact="prevalence" post="to decrease significantly compared to baseline, since PS becomes"/>
  <result pre="k mean individuals over-estimate population vaccine coverage, such that perceived" exact="infection" post="risk decreases instead of increasing, and HIV prevalence declines"/>
  <result pre="that perceived infection risk decreases instead of increasing, and HIV" exact="prevalence" post="declines only slightly compared to pre-vaccine prevalence (Supplementary Figure"/>
  <result pre="increasing, and HIV prevalence declines only slightly compared to pre-vaccine" exact="prevalence" post="(Supplementary Figure S12). Hence, underestimation of population vaccine coverage"/>
  <result pre="utility for protected sex UPS decreases both actual and perceived" exact="infection" post="risk, as expected (Supplementary Figures S14, S15). In contrast,"/>
  <result pre="S15). In contrast, increasing the vaccine efficacy decreases the HIV" exact="prevalence" post="but slightly increases the perceived infection risk (Supplementary Figure"/>
  <result pre="efficacy decreases the HIV prevalence but slightly increases the perceived" exact="infection" post="risk (Supplementary Figure S16). This occurs because a higher"/>
  <result pre="vaccine coverage. Increasing the transmission rate τ increases the HIV" exact="prevalence" post="(Supplementary Figure S17) similar to the observations found in"/>
  <result pre="the offers of unprotected sex, which can increase the perceived" exact="infection" post="risk in the population and make some HIV− individuals"/>
  <result pre="As a result of these other feedback loops, both HIV" exact="prevalence" post="and the rate of unprotected sex acts with HIV+"/>
  <result pre="not emerge after the interventions. At other parameter values, HIV" exact="prevalence" post="can increase as a result of the interventions. For"/>
  <result pre="making the utility of unprotected sex sufficiently attractive, then HIV" exact="prevalence" post="could actually rise under HAART (Supplementary Figure S4). Also,"/>
  <result pre="who are offered unprotected sex increase their estimate of HIV" exact="prevalence" post="in the population. This was motivated by studies that"/>
  <result pre="analysis. We found that increasing or decreasing this parameter influences" exact="prevalence" post="and risk assessment as we might expect, but our"/>
  <result pre="primary qualitative conclusion that multiple pathways can determine behavior and" exact="prevalence" post="remains unchanged under this sensitivity analysis. Furthermore, exploring the"/>
  <result pre="BlowerS. M., ServiceS. K. &amp;amp; OsmondD.Calculating the odds of HIV" exact="infection" post="due to sexual partner selection. AIDS Behav.1, 273–274 (1997)."/>
  <result pre="the HIV epidemic: A mathematical analysis in the context of" exact="treatment" post="as a prevention. PLoS One810.1371/journal.pone.0062321 (2013). JacquezJ. A., SimonC."/>
  <result pre="SattenspielL. &amp;amp; PerryT.Modeling and analyzing HIV transmission: the effect of" exact="contact" post="patterns. Math. Biosci.92, 119–199 (1988). NagelkerkeN. J.et al.Modelling HIV/AIDS"/>
  <result pre="89–96 (2002).11953786 AdamsB.et al.HIV dynamics: modeling, data analysis, and optimal" exact="treatment" post="protocols. J. Comput Appl Math.184, 10–49 (2005). PrejeanJ.et al.Estimated"/>
  <result pre="Bio.66, 143–166 (2004).14670534 Velasco-HernandezJ. X. &amp;amp; HsiehY.-H.Modelling the effect of" exact="treatment" post="and behavioral change in HIV transmission dynamics. J. Math"/>
  <result pre="D.Male clients of brothel prostitutes as a bridge for HIV" exact="infection" post="between high risk and low risk groups of women"/>
  <result pre="August 2014). Averting HIV and AIDS. Universal access to HIV" exact="treatment" post="(2013). Available at: http://www.avert.org/universal-access-hiv-treatment.htm (Accessed: 15th August 2014). University"/>
  <result pre="2015). Hepatitis B Foundation: Cause for a cure Post exposure" exact="treatment" post="summary of guidelines, (2012) Available at: http://www.hepb.org/professionals/post-exposure_guidelines_summary.htm (Accessed: 1st"/>
  <result pre="average bt-value for HIV+ (red) and HIV—(green) populations; (f) HIV" exact="prevalence" post="(percentage of the population currently infected). Figure 2 Baseline"/>
  <result pre="bt-value for HIV+ (red) and HIV− (green) populations; (f) HIV" exact="prevalence" post="(percentage of population currently infected). Figure 4 Baseline scenario"/>
  <result pre="bt-value for HIV+ (red) and HIV− (green) populations; (f) HIV" exact="prevalence" post="(percentage of population currently infected). Figure 6 Baseline scenario"/>
  <result pre="through US. This value is modified according to stage of" exact="infection" post="(see Supplementary Table S3) 0.0242 UPS Protected sex utility."/>
  <result pre="ζ Probability an individual who identifies as HIV− will seek" exact="testing" post="to determine if they are infected. 0.1 per timestep"/>
 </snippets>
</snippetsTree>
